“Our CodeEvolver technology enabled a computational design strategy to create an enzyme that eliminates several manufacturing steps and performs in a high-pH environment.  This proprietary enzyme will now be used to streamline vibegron manufacturing,” said Codexis president and chief executive officer John Nicols. “This agreement with KYORIN is another example of the significant value our technology brings in developing high-performing, value-added enzymes with utility from R&D to commercial-scale manufacturing. We are delighted to enter into this supply agreement with KYORIN.”